Poor Performance Status Associated With Inferior Tarlatamab Outcomes in a Large, Multi-institution Real-World Database of Patients With 2L + ES-SCLC

Clinical Lung Cancer · Published 2026-07-02 · DOI 10.1016/j.cllc.2026.07.001

Free full text

Authors (9)

Adam A. Barsouk, Maxim Yaskolko, Jonathan H. Sussman, Lova Sun, Aditi Puri Singh, Roger B. Cohen, Charu Aggarwal, Melina E. Marmarelis, Corey J. Langer

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Barsouk, A., Yaskolko, M., Sussman, J., et al. (2026). Poor Performance Status Associated With Inferior Tarlatamab Outcomes in a Large, Multi-institution Real-World Database of Patients With 2L + ES-SCLC. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2026.07.001

Related articles

• Optimizing Tarlatamab Delivery in Small Cell and Neuroendocrine Lung Cancer: Real-World Insights into Step-Up Dosing and Prophylactic Tocilizumab Use · Clinical Lung Cancer · 2025 · Cites or is cited by this article · Same journal
• Real-World Safety and Effectiveness of Neoadjuvant Chemoimmunotherapy in Squamous Cell Lung Cancer: A Retrospective European Multicentre Study · Clinical Lung Cancer · 2026 · Same journal
• Next-Generation Sequencing Completion and Timeliness Using a Reflex Testing Protocol for Patients with Stage II to IV Nonsquamous Non–Small Cell Lung Cancer · Clinical Lung Cancer · 2026 · Same journal
• Brief Report: A Pilot Study Evaluating the Feasibility, Safety, and Compliance With a Fasting-Mimicking Diet in Patients With Metastatic Non–Small Cell Lung Cancer · Clinical Lung Cancer · 2026 · Same journal
• Complete Spontaneous Regression of Lung Adenocarcinoma With No Residual Malignancy After Surgical Resection: A Case Report · Clinical Lung Cancer · 2026 · Same journal
• Clinicogenomic Predictors of First-line Immune Checkpoint Inhibitor Outcomes in Non–Small Cell Lung Cancer: A Nationwide C CAT Cohort From Japan · Clinical Lung Cancer · 2026 · Same journal
• Streamlining the Frequency, Conduct, and Location of Assessments in Registrational Lung Cancer Clinical Trials for Supplemental Applications: Recommendations of a LUNGevity Foundation Multistakeholder Working Group · Clinical Lung Cancer · 2026 · Same journal
• Impact of Programmed Death Ligand 1 Expression on Outcomes in Stage I-II Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinoma · Clinical Lung Cancer · 2026 · Same journal
• Consolidative Radiotherapy for Extensive-Stage Small Cell Lung Cancer: Outcomes Based on Completeness of Consolidation and Oligometastatic State · Clinical Lung Cancer · 2026 · Same journal
• Adjuvant Therapy After Pathologic Complete Response to Neoadjuvant Immunochemotherapy in Non–Small Cell Lung Cancer: A Multicenter Retrospective Real-World Study · Clinical Lung Cancer · 2026 · Same journal